Amylyx Pharmaceuticals, Inc. (AMLX)
Thursday, November 5, 2026
Key stats
Chart
Price, buy and sell signals and key levels on one chart.
Past 1Y
MA21MA180
SignalsBuyEarly buySellEarly sellTurning pointsSwing highSwing low
Up dayDown day
Thursday, November 5, 2026
Price, buy and sell signals and key levels on one chart.
Amylyx Pharmaceuticals (AMLX) closed at $35.11 on Aug 18, 2026, up 63.8% on the day. The stock is up 97.8% over the past month, up 164.3% over three months and up 190.6% year to date. It is trading at its 52-week high of $24.60. The close sits above its 50-day moving average ($18.52) and above its 200-day moving average ($15.31).
AMLX is scheduled to report earnings on Nov 5, 2026.
Amylyx Pharmaceuticals is scheduled to report on Nov 5, 2026.
Yes — the Aug 18, 2026 close of $35.11 is 129.3% above the 200-day average of $15.31.
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.